Freeline Data Update in Haemophilia B

Interview
Published 07 Feb 2020

Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview

Syncona’s Chief Investment Officer, Chris Hollowood provides Syncona’s view on the encouraging new data presented by Freeline from its Phase 1/2 B-AMAZE trial investigating a novel gene therapy, FLT180a, for Haemophilia B at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).